68 Facts About Scott Gottlieb

Scott Gottlieb was born on June 11,1972 and is an American physician and investor who previously served as the 23rd commissioner of the Food and Drug Administration from May 2017 until April 2019.

Scott Gottlieb is presently a senior fellow at the conservative think tank the American Enterprise Institute, a partner at the venture capital firm New Enterprise Associates, and a member of the board of directors of drug maker Pfizer, Inc and gene sequencing company Illumina, Inc Gottlieb is a contributor to cable financial news network CNBC and the CBS News program Face the Nation.

Scott Gottlieb's forthcoming book, The Miracle Century: Making Sense of the Cell Therapy Revolution, traces the scientific achievements that propelled progress in cell therapies.

Scott Gottlieb was previously a resident fellow at AEI from 2007 to 2017, prior to joining the FDA as Commissioner in May 2017.

Scott Gottlieb is a graduate of East Brunswick High School and received his bachelor's degree in economics from Wesleyan University.

Scott Gottlieb attended medical school at Icahn School of Medicine at Mount Sinai and completed his residency in internal medicine at the Mount Sinai Hospital.

Scott Gottlieb worked for the US Food and Drug Administration from 2002 to 2003 and 2005 to 2007.

Scott Gottlieb first served as a senior advisor to the FDA Commissioner and then as the FDA's Director of Medical Policy Development from 2002 to 2003.

Scott Gottlieb helped initiate the FDA's generic drug user fee program and the Physician Labeling Rule.

Scott Gottlieb returned to the FDA from 2005 to 2007 as the agency's Deputy Commissioner for Medical and Scientific Affairs, where he was appointed to the Senior Executive Service and granted a top secret security clearance.

Scott Gottlieb was a member of the Biodefense Interagency Working Group to help draft a strategic plan for US biodefense countermeasures.

Scott Gottlieb worked on advancing a framework for the creation of a generic drug user fee program, final implementation of the physician labelling and pregnancy labelling rules, and pandemic preparedness.

In that latter role, Scott Gottlieb recused himself from parts of the planning effort on a bird flu vaccine in 2005, because he had done consulting work for GSK, whose products might be used.

Scott Gottlieb practiced internal medicine as an attending physician at New York University's Tisch Hospital in New York City.

In 2007, Scott Gottlieb became a venture partner at New Enterprise Associates, the world's largest venture capital firm by assets under management.

Scott Gottlieb served as an active investing partner in the firm's healthcare division.

Scott Gottlieb served on the boards of directors of several NEA portfolio companies, including Bravo Health and American Pathology Partners.

Scott Gottlieb remained at NEA from 2007 until his appointment to be FDA Commissioner in May 2017.

Scott Gottlieb was an independent director at Tolero Pharmaceuticals and Daiichi Sankyo Inc and a member of GlaxoSmithKline's product investment board, which made decisions on which drugs GSK would take forward in development.

Scott Gottlieb was a senior healthcare advisor to BDO and a partner at a merchant bank with a focus on healthcare.

Scott Gottlieb previously advised the 2016 presidential campaign of Wisconsin Governor Scott Walker.

Scott Gottlieb was nominated as FDA Commissioner in March 2017.

Politico reported that Scott Gottlieb was "expected to push the boundaries of FDA reviews and using new authority" to streamline approvals using the 21st Century Cures Act.

Scott Gottlieb testified before the Senate Committee on Health, Education, Labor and Pensions.

FDA later sought, and received, authority that Scott Gottlieb and requested from Congress to be able to require the market withdrawal of opioid drugs when the agency had safety concerns that arose as a result of the illicit use of opioid drugs.

On July 28,2017, Scott Gottlieb delayed application deadlines on new tobacco products, including premium cigars and electronic cigarettes, to provide sufficient time to finalize regulations on how those products would be regulated by the FDA, and at the same time, announced that the FDA would take steps to regulate nicotine levels in combustible cigarettes to render the combustible cigarettes "minimally or non-addictive," and to regulate flavored tobacco products, including menthol cigarettes.

In December 2017, Scott Gottlieb unveiled a policy to step up FDA's oversight of homeopathic drugs, which had previously gone largely unregulated.

In May 2018, Scott Gottlieb asked federal courts on opposite sides of the country to permanently stop two stem cell companies from operating after reports of patients being blinded by their treatments and released new guidelines on how the FDA would set enforcement priorities.

Scott Gottlieb announced an initiative to accelerate development of FDA regulated cell and gene therapies in anticipation of a surge of new applications for commercial products.

In September 2018, citing an epidemic of use of electronic cigarettes by teenagers, Scott Gottlieb announced that the FDA would seek to ban flavors in e-cigs as a way to reduce their appeal to youth.

Scott Gottlieb called into question the motives behind the decision by Altria to take a minority stake in Juul and accused the manufacturer of reneging on commitments and representations it had made to FDA.

Scott Gottlieb pursued policies to address barriers to the approval of complex generic drugs, including generic, functionally equivalent alternatives to EpiPen.

Scott Gottlieb had fought to maintain FDA control over the review and approval of medical products intended to support the war fighter after the Pentagon had sought to acquire that authority for itself as part of the National Defense Authorization Act.

Ultimately, the compromise was to retain the authority with the FDA but for the FDA to commit to offer products intended for the battlefield a higher priority of review, reflecting the compromise provision that Scott Gottlieb had put forward.

Scott Gottlieb committed to make fighting opioid addiction one of his highest priorities as Commissioner.

Scott Gottlieb announced that the FDA would pursue a comparative approval standard for new opioids seeking to come to market, arguing that new opioid painkillers should show advantages over existing opioid drugs to win FDA approval.

Scott Gottlieb undertook a series of new steps to rationalize prescribing as a way to reduce exposure to opioid drugs in order to cut the rate of new addiction.

In February 2019, Scott Gottlieb took action to curtail the marketing of 17 dietary supplements that were making unlawful and unproven medical claims to treat Alzheimer's disease and, at the same time, unveiled a set of policy steps to strengthen the FDA's oversight of dietary supplements that was billed as the most significant modernization of the agency's regulation of supplements in 25 years.

In Spring 2019, Scott Gottlieb took a series of actions to create a new framework for the development and FDA oversight of artificial intelligence medical devices.

In March 2019, Scott Gottlieb pressed for the market withdrawal of certain cosmetics because they were found to contain asbestos, at the same time that he announced a set of new proposals to strengthen oversight of the cosmetics industry, winning praise from legislators who had been pressing for similar reforms.

On March 5,2019, Scott Gottlieb announced his resignation as FDA Commissioner, effective in about a month.

Scott Gottlieb said that he wanted to spend more time with his family.

On March 13,2019, Scott Gottlieb moved to restrict sales of flavored e-cigarettes to try to reduce the soaring rate of teenage vaping.

Scott Gottlieb sought and received money from Congress to hire dozens of more staff to inspect 100,000 packages per year that had been flagged as suspicious by customs agents, up from a prior capacity of roughly 40,000.

Scott Gottlieb was elected as an independent member of the board of directors of Pfizer, Inc in June 2019.

Scott Gottlieb joined the Illumina, Inc board of directors in February 2020 and the National Resilience, Inc board of directors in November 2020, where he was one of the original venture investors.

Scott Gottlieb is a member of the boards of trustees of the Mount Sinai Health System and Wesleyan University.

Scott Gottlieb is a regular contributor to the Journal of the American Medical Association's Health Forum.

On February 12,2020, Scott Gottlieb testified before the Senate Committee on Homeland Security and Governmental Affairs on preparedness for the novel coronavirus and future pandemic threats.

Since April 2020, Scott Gottlieb has advised several governors on the COVID-19 pandemic.

Scott Gottlieb joined Maryland Governor Larry Hogan's COVID-19 response team and Massachusetts Governor Charlie Baker's COVID-19 advisory board.

Scott Gottlieb has advised Connecticut Governor Ned Lamont as a member of the Reopen Connecticut Advisory Group.

On November 20,2020, it was announced that Scott Gottlieb would serve on Montana's Governor-elect Greg Gianforte's COVID-19 task force.

Scott Gottlieb was criticized by Substack author Alex Berenson for contacting Twitter; Berenson alleged it was to get him removed from the platform.

Scott Gottlieb was a member of the Public Policy Committee to the Society of Hospital Medicine and an editorial board member of the journal Value Based Cancer Care.

Scott Gottlieb served as an adviser to the National Comprehensive Cancer Network, the National Coalition for Cancer Survivorship.

Scott Gottlieb is a member of the advisory board to the Milken Institute's FasterCures and the National Institute for Health Care Management.

Scott Gottlieb was a staff writer of the British Medical Journal from 1997 to 2005 and a senior editor of the Pulse section of the Journal of the American Medical Association from 1996 to 2001.

Scott Gottlieb is a Contributor to the Journal of the American Medical Association's Health Forum and a regular contributor to the editorial page of The Wall Street Journal and The Washington Post and wrote regularly for Forbes.

In 2020 and 2021, Scott Gottlieb authored a weekly column for the editorial page of the Wall Street Journal.

Scott Gottlieb was a frequent and early critic of the Patient Protection and Affordable Care Act.

Scott Gottlieb wrote an editorial in The Wall Street Journal, on the day of the health plan's launch, predicting the ensuing problems with the healthcare.

Scott Gottlieb argued that studies showed some patients who received Medicaid had worse outcomes, including death, when they had certain conditions like head and neck cancer, compared to patients who had no insurance coverage at all.

Scott Gottlieb observed that in these cases, uninsured patients had access to newer medicines through free patient assistance programs, whereas federal law prevented Medicaid patients from getting access to these free drug programs because they were enrolled in Medicaid.

In October 2019, Scott Gottlieb wrote a feature for the conservative editorial page of The Wall Street Journal, where he called for a "reckoning" when it comes to the impasse between state laws legalizing cannabis and the policy of federal prohibition that outlaws cannabis but is largely unenforced.

In that op-ed, Scott Gottlieb called for a pathway toward federal legalization of cannabis that would allow, among other reforms, easier access to the compound for research while exerting stricter and more uniform regulation over products.

In January 2020, Scott Gottlieb wrote several articles warning about the spread of COVID-19 in the United States.

Scott Gottlieb examined the systemic shortcomings of the US response to the COVID-19 pandemic in his new book, Uncontrolled Spread: Why COVID-19 Crushed Us and How We Can Defeat the Next Pandemic, which was released on September 21,2021 by HarperCollins.